Medtech Trends 2026: How Global Pressures Are Reshaping the Medical Device Industry

Executive Summary

The global medical technology (medtech) sector is navigating a convergence of structural pressures that will reshape market economics and corporate strategy through 2026 and beyond. According to a recently published analysis by Clarivate, five trends stand out as particularly consequential: the continued expansion of China's volume-based procurement (VBP) with new pricing and allocation rules; the accelerating migration of procedures from hospitals to outpatient and ambulatory surgery centers (ASCs), particularly in the United States; the persistent impact of tariffs, geopolitical friction, and supply chain volatility on manufacturing footprints; the clinical and market ripple effects of GLP-1 weight-loss therapies on surgical volumes and adjacent device markets; and the rise of enabling technologies—robotics, imaging, navigation, and digital workflows—that are shifting competition from individual devices toward integrated platforms.

These developments are not isolated policy or regulatory changes. They reflect deeper global realities: the maturation of healthcare markets in emerging economies, the cost-containment imperative across developed health systems, the securitization of medical supply chains, and the digital transformation of clinical care. For multinational medtech firms, investors, and policymakers, understanding these dynamics is essential.

Introduction

For decades, the medtech industry enjoyed predictable growth driven by demographic demand and technological innovation. That era is giving way to a more complex environment. Global competition, differential pricing regulations, and non-traditional competitors are eroding traditional moats. Meanwhile, advances in adjacent fields such as pharmacology and artificial intelligence are blurring the boundaries between devices, drugs, and digital services.

In this context, Clarivate's "Medtech Trends to Watch 2026" report—published in April 2026—offers a data-driven roadmap. The findings highlight a paradox: even as demand for medical procedures grows worldwide, the mechanisms for paying for them are tightening, as are the margins for manufacturers. This article distills those trends into an internationally oriented analysis, focusing on the strategic, economic, and geopolitical factors at play.

Background: A Sector in Transition

The medical device industry has historically been characterized by high margins and fragmented markets. Regulatory approvals, clinician preferences, and hospital procurement systems have acted as high barriers to entry. Yet the past five years introduced disruptive changes: the COVID-19 pandemic exposed fragile supply chains; inflation and labor costs squeezed providers; and governments, struggling with fiscal constraints, accelerated policies to lower device prices.

China, the world's second-largest healthcare market, has become a policy laboratory. Its volume-based procurement (VBP) program, launched in 2018 to reduce drug and device prices, initially targeted high-volume generic items. By 2026, however, VBP has expanded to sophisticated categories including coronary stents, joint replacements, and even advanced capital equipment components—often bringing price cuts of 50–90%. For multinationals, participation in China increasingly requires accepting terms that may not align with global price structures, complicating arbitrage and penetration strategies.

Simultaneously, healthcare delivery is decentralizing. The United States, which accounts for roughly 40% of global medtech revenues, has been shifting procedures away from acute-care hospitals for over a decade. This migration is now central to product planning and commercial execution.

These two forces—global pricing reform and outpatient migration—may seem distinct, but they share a common driver: the need to deliver care more efficiently. They also set the stage for the other trends outlined in this analysis.

Main Analysis: The Five Trends Defining 2026

1. China's VBP Expansion: A New Competitive Template

Clarivate's research emphasizes that China's latest national VBP round is not merely an extension of prior policy but a qualitatively different mechanism. The new anchor-price logic links reimbursement rates to a weighted basket of global median prices, forcing multinationals to consider whether they can sustain their business models in a market where domestic rivals enjoy structural advantages.

Deeper price compression and allocation rules that favor local manufacturers are accelerating the indigenous innovation agenda. Chinese companies such as MicroPort, United Imaging, and NaO, once perceived as domestic suppliers, are now entering Southeast Asia, Latin America, and even Europe with cost-competitive portfolios. For international firms, the strategic question is no longer "How do we protect our China business?" but "How do we compete with Chinese-origin technology globally?"

The policy significance extends beyond healthcare: VBP reflects the Chinese state's broader drive for self-sufficiency in advanced manufacturing. Medical devices are a strategic sector under the 'Healthy China 2030' plan, and VBP is being used not just to control costs but to reshape the industrial landscape.

2. The Outpatient Migration: Opportunity and Complexity

The U.S. Centers for Medicare & Medicaid Services' (CMS) 2026 OPPS/ASC Final Rule expands the list of procedures eligible for reimbursement in ambulatory surgery centers. This includes higher-acuity interventions like cardiac ablation, which previously required inpatient stays. While the U.S. is the clearest exponent of this shift, similar trends are visible in Europe, Australia, and parts of Asia, where governments seek to reduce hospital bed occupancy and lower system costs.

For device manufacturers, the outpatient transition has profound implications. Products designed for hospital cath labs may require modifications to fit the workflow of ASCs, which emphasize speed, smaller device profiles, and lower capital cost. Reimbursement rates are typically lower in ASCs, pressuring prices. The commercial model also changes: instead of selling through hospital purchasing departments with group purchasing organizations, manufacturers may need to engage with individual surgeon-investors and small practice entities.

This trend amplifies the importance of economic value propositions. Device companies must prove that their products not only improve clinical outcomes but also enable same-day discharge and reduce total episode cost—a shift that rewards innovation in minimally invasive technology and digital patient monitoring.

3. Trade and Supply Chain Pressures: The Geoeconomics of Medtech

The tariffs imposed during the U.S.–China trade war, followed by pandemic-era shortages and the Red Sea shipping disruptions, have permanently altered medtech manufacturing strategy. Clarivate highlights that tariffs on medical devices and raw materials fluctuate, but the underlying volatility is now perennial. In 2026, more than 60% of medical device firms report having dual-sourced or relocated primary production sites compared to 2020.

Key materials—including semiconductors, specialty stainless steel, polymers, and rare-earth magnets—remain concentrated in a few jurisdictions. The shortage of rare-earth elements used in motors for robotic systems and imaging devices is a looming bottleneck. In response, leading manufacturers are not merely moving factories; they are redesigning supply chains for agility.

The economic consequences are significant. Reshoring manufacturing to the U.S. or Europe increases production costs by 20–35%, which in markets with reimbursement constraints may transfer to higher hospital prices or squeezed margins. Countries like Vietnam, Mexico, and Malaysia are emerging as new hubs, not just for labor but as recipients of sophisticated manufacturing that requires skilled technicians. This redistribution of industrial capacity may have long-term effects on national trade balances and technological capabilities.

4. GLP-1 Therapies: A Disruptive Force Beyond Pharma

The rise of GLP-1 receptor agonists (for diabetes and obesity) is often viewed as a pharmaceutical story, but its effects are cascading through medtech. Clarivate notes that bariatric surgery volumes are experiencing a negative impact, particularly for sleeve gastrectomy and gastric bypass procedures, as patients initially achieve weight loss pharmacologically. However, the effect is not uniform: procedures that are more effective at reversing obesity-related complications, such as duodenal switch, are seeing slower decline.

Beyond bariatrics, GLP-1s are altering cardiovascular monitoring, diabetes care (glucose sensors, pumps), and even sleep apnea—since weight loss reduces obstructive sleep apnea severity. Device makers in these spaces must consider how their target populations may shift. For example, if GLP-1s reduce the incidence of diabetes, future demand for insulin pumps might be lower; conversely, the need for glucose monitoring to manage GLP-1 side effects could increase.

Clinically, GLP-1s may delay the point at which patients become eligible for surgery, potentially increasing the risk of complications later. This creates a complex interaction between drug and device adoption. Medtech firms must now track prescription rates and conversion rates as indicators for procedure demand, integrating pharmaceutical data into their forecasting models.

5. Enabling Technologies and Platform Competition

Traditionally, medtech companies competed on discrete products: a better stent, a more precise scalpel, an easier-to-use endoscope. That model is eroding. Clarivate identifies that enabling technologies—robotics, advanced imaging, navigation systems, and digital workflow software—are becoming the core differentiators. Product development is shifting toward "platform ecosystems" that integrate these technologies across the surgical continuum.

For example, a robotic surgical system is no longer a mechanical arm in an operating room. It is paired with intraoperative imaging that updates navigation in real time; software that integrates with hospital IT systems to report outcomes; and data analytics that predict patient trajectories. The company that controls the platform acquires an outsized share of the value chain, locking in both surgeons and institutions.

Platform-based competition raises barriers to entry for pure-play device manufacturers. It demands investments in software engineering, cybersecurity, and user experience of a kind previously unseen in medtech. It also invites competition from technology giants such as Alphabet, Sony, and Medtronic's digital divisions. In 2026, we expect to see M&A activity concentrated on acquisitions of startups with AI algorithms and platform architecture rather than on product differentiation.

International Impact

These trends do not occur in silos. They interact across borders and sectors, producing effects that restructure global trade, investment, and public health priorities.

Global economy and trade: The reconfiguration of medical supply chains is a microcosm of broader de-risking efforts. Countries are applying investment screening to medical technology deals, and medical devices are being treated as sensitive assets. This could hamper technology transfer but also open opportunities for domestic producers in emerging markets. Export controls on advanced chip technology may eventually impact the development of AI-diagnostic tools, affecting global health equity.

Business and investment: Multinational medtech firms face an equity market that is punishing late-stage pipelines and rewarding strategic agility. The need to comply with China's price-control mechanisms while preserving patent value leads to intricate corporate structures exploiting different tax regimes and local partnerships. Meanwhile, sovereign wealth funds in the Gulf and Asia are increasingly investing in medical device startups as part of economic diversification strategies.

Public policy: The success of GLP-1 therapies in reducing obesity-related morbidity could strain health budgets if adopted as a public health tool. Policymakers will demand data on indirect effects, such as lower demand for joint replacements due to improved weight management, in order to assess cost-effectiveness. Similarly, cost-benefit analyses of outpatient expansion must account for provider convenience and patient outcomes.

Technology standards: Platform competition is pushing toward proprietary ecosystems, which may impede interoperability. International bodies such as the International Medical Device Regulators Forum (IMDRF) will face pressure to establish common standards for software as a medical device (SaMD), particularly as AI becomes embedded in surgical platforms.

Strategic Perspectives

For corporate leaders, the takeaways are clear:

• Diversification is not optional: Companies must build geographically divisible supply chains with select factories serving specific regions, and they must consider not just tariff costs but carbon border taxes and environmental standards.
• Pricing power now derived from evidence: The era of across-the-board price increases is over. Companies need to demonstrate value through randomized trials that show reduction in total care costs, not just clinical superiority.
• Platforms are the new moat: Investment in data infrastructure and integrations should be prioritized, even if it results in near-term margin erosion. Long-term, the company that owns the data from a platform will have the ultimate control.
• Monitor patient behavior as a leading indicator: The GLP-1 effect highlights how patient preferences shift rapidly. Regular recalibration of sales forecasts and product roadmaps should incorporate prescribing trends and societal health changes, not only procedural statistics.

From a government and institutional investor perspective, the focus should be on supporting innovation ecosystems that ensure resilience. For example, public–private partnerships in semiconductor advanced packaging for medical devices, or the creation of rare-earth recycling capabilities, can mitigate dependency.

Future Outlook: 2026–2036

Looking ahead to the next ten years, several projections can be made:

By 2028, the outpatient segment will account for more than 60% of all surgical procedures in the U.S., and comparable trends will begin showing in Western Europe and Japan, forcing device designs to be inherently portable and solo-practice compatible.

By 2030, Chinese medtech firms are likely to hold 25–30% of the global market for high-volume consumables, driven by VBP-enforced scale. Their expansion will not be limited to low-cost items; they will be competitors in advanced implantables and diagnostic devices, achieving parity through modular innovation.

By 2032, GLP-1 drugs with oral bioavailability and lower cost will have expanded treatment beyond obesity, and they will likely be used as adjuncts to treat heart disease, sleep apnea, and potentially arthritis. This will decrease the volume of certain implant surgeries but increase the population of healthier elderly people who elect surgeries for maintenance. The medtech industry will transform from a method of repairing organs to a partner in managing chronic disease.

By 2035, platform companies will resemble today's enterprise software giants. The medical device sector will adopt a layered structure: infrastructure providers (such as AI algorithms and interoperable robotic arms), applications (the actual procedures), and services (data analytics and patient recovery). The concept of a "device" may dissolve into a combination of disposables and digital tools.

Given these horizon-line changes, international cooperation will be crucial. The World Health Organization (WHO) and bilateral agreements will need to align on cybersecurity norms for software-integrated medical devices, and climate agreements may someday govern the carbon footprint of medical supply chains. The Strategic Health Operations Centre, if appropriately resourced, could become a forum for such discussions.

Conclusion

As 2026 progresses, the medtech industry stands at a crossroads. The product cycles that once took 10 years now compress to just a few; the regulatory landscape is fragmented but converging toward outcome-based evidence; and the participants are no longer solely device manufacturers but powerful cross-sector alliances. The companies that succeed will not be the ones that cling to historical modes but those that embrace the complexity of a multipolar, data-rich, and policy-driven world. For the international community, ensuring that these transformations benefit patient populations and healthcare systems requires continuous dialogue among industry, government, and academia. Events over the coming 12 to 24 months will test the sector's ability to navigate these pressures without compromising its technical excellence and clinical mission.